THREE-YEAR DATA from the phase 3b BE RADIANT trial suggest that bimekizumab delivers rapid and durable improvements in patient-reported symptoms and quality of life for people with moderate-to-severe plaque psoriasis.
The findings include results from the 48-week double-blind phase and a 96-week open-label extension (OLE), providing a total of three years of treatment data. In the initial randomised period, 743 patients received either bimekizumab or secukinumab; 654 entered the extension phase.
Patient-reported outcomes (PROs) were assessed using the Psoriasis Symptoms and Impacts Measure (P-SIM), focusing on itching, skin pain, and scaling, alongside concurrent achievement of Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) responses.
Bimekizumab Demonstrates Rapid Symptom Relief by Week 4
Improvements with bimekizumab were evident as early as Week 4. Among patients initially randomised to bimekizumab, 34.0% reported no itching at Week 4, compared with 25.1% in the secukinumab group. Similarly, 74.5% versus 60.0% reported no skin pain, and 46.1% versus 21.6% reported no scaling.
By one year, these differences persisted. A total of 60.9% of patients originally assigned to bimekizumab reported no itching compared with 48.1% of those assigned to secukinumab. Rates of no skin pain were 78.6% versus 70.8%, and no scaling 70.5% versus 49.7%, respectively.
Bimekizumab also led to higher rates of complete skin clearance combined with minimal impact on quality of life. At Week 4, 11.5% of bimekizumab-treated patients achieved PASI=0 and DLQI 0/1, compared with 4.6% in the secukinumab arm. By Year 1, this had increased to 61.7% versus 42.7%.
Bimekizumab Maintains Durable Efficacy Through 3 Years
At the end of the double-blind phase, patients originally assigned to bimekizumab continued treatment, while those on secukinumab switched to bimekizumab. At OLE entry, 69.2% of continuous bimekizumab patients had achieved concurrent PASI=0 and DLQI 0/1, compared with 48.5% of those switching. Following the switch, responses in the secukinumab/bimekizumab group increased, and by Year 3 high response rates were maintained in both groups (62.2% and 63.8%, respectively).
Overall, the authors conclude that bimekizumab’s clinical efficacy translates into meaningful and sustained improvements in symptoms and health-related quality of life over three years, with additional gains seen in patients who switched from secukinumab.
Reference
Augustin M et al. Three-year patient-reported outcomes from bimekizumab for plaque psoriasis: the BE RADIANT randomized clinical trial with open-label extension. JAMA Dermatol. 2026;doi: 10.1001/jamadermatol.2025.6055.
